Bone News and Research

RSS

NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers

A combination of nutrients called NT-020 promoted adult neural stem cell proliferation in aged rats and boosted their memory performance, reported University of South Florida researchers studying natural therapeutic approaches to promoting the health of neurons in the aging brain.

21 Jul 2010

Mesoblast gains Australian TGA licence to manufacture Mesenchymal Precursor Cell products

Australian regenerative medicine company, Mesoblast Limited, today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cell (MPC) products.

21 Jul 2010

BioMimetic Therapeutics closes underwritten public offering

BioMimetic Therapeutics, Inc., announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised their option to purchase an additional approximately 642,000 shares of common stock. As a result, BioMimetic sold a total of approximately 5.64 million shares of its common stock at a price to the public of $8.50 per share.

21 Jul 2010

Genentech disappointed with FDA ODAC's recommendation against Avastin

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one that use of Avastin® (bevacizumab) in combination with paclitaxel for previously untreated (first-line) advanced HER2-negative breast cancer be removed from Avastin's U.S. label.

21 Jul 2010

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation. The award will fund a "first in childhood leukemia" multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML). Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries.

21 Jul 2010

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism, which is a frequent complication of end stage renal disease.

20 Jul 2010

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

The flood of scientific evidence on omega-3 eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) has significantly buoyed the credibility of polyunsaturated fatty acids (PUFAs) as vital functional ingredients. Heightened consumer awareness has had a telling effect on the healthy growth charts of the marine and algae oil omega-3 ingredients market.

20 Jul 2010

Athletes who undergo tissue transplant surgery for knee damage can return to sports: Study

Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010

Vitamin D supplements could help preteen girls set stage for a lifetime of strong bones: Study

"Eat your veggies," "Don't run with scissors" and now "Take your calcium and vitamin D." A clinical study conducted at the School of Exercise Science at Australian Catholic University has shown that taking high quality calcium supplements like USANA's Active Calcium could help preadolescent girls set the stage for a lifetime of strong, mineral-rich bones.

20 Jul 2010

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Bioengineers from Rice University's BioScience Research Collaborative have won a $1.7 million grant from the National Institutes of Health to develop an injectable mix of polymers and adult stem cells that can spur the growth of new cartilage in injured knees and other joints.

20 Jul 2010

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

ZIOPHARM Oncology, Inc. today announced the initiation of the pivotal Phase III clinical trial for palifosfamide in patients with front-line metastatic soft tissue sarcoma. The study, called PICASSO 3, is an international, randomized, double-blinded, placebo-controlled trial designed to enroll approximately 424 patients with metastatic soft tissue sarcoma who have never been treated with chemotherapy for metastatic disease.

20 Jul 2010

Arthroscopic hip surgery may help athletes resume their sport back: Study

Hip problems can sideline even the best athletes, but a new study led by orthopedic experts from Rush University Medical Center indicates that the use of minimally invasive arthroscopic surgery to treat painful disorders of the hip may give athletes who undergo the procedure another opportunity to resume their sport back at their pre-injury level of competition.

20 Jul 2010

Corgenix, ELITech establish broad strategic alliance

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents, today announced a broad strategic alliance.

19 Jul 2010

ThermoGenesis anticipates $7.3 million revenue for fourth-quarter 2010

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today it expects revenues for the quarter ended June 30, 2010, to be approximately $7.3 million and to report a small net loss for the quarter, in the range of $150,000 to $450,000, subject to final audit adjustments. The Company plans to report complete final results for the fourth quarter and all of fiscal 2010 and provide its outlook for fiscal 2011 in mid-September.

19 Jul 2010

Over 50% of neurosurgical procedures performed on Afghan children were for battlefield-related injuries

War inevitably takes a tragic toll on innocent bystanders including civilians and children. Military neurosurgeons have a long history of helping US and coalition troops and civilians overcome devastating and life-threatening neurological injuries incurred as a result of military strife. While stationed at US military facilities, neurosurgeons also contribute to invaluable humanitarian efforts, operating on patients with injuries and conditions unrelated to battle.

17 Jul 2010

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Scientists from the Department of Molecular Immunology, Institute of Biology III, Faculty of Biology and the Centre for Biological Signalling Studies, BIOSS have discovered a new mechanism that drives the development of B-lymphocytes in our bone marrow. B-lymphocytes are an important part of our immune system. Upon their activation they produce the antibodies protecting us from infections.

17 Jul 2010

Maxygen's option and licensing arrangement with Cangene expires

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that its option and licensing arrangement with Cangene Corporation has expired. Under the agreement, Maxygen had granted Cangene an option to obtain an exclusive license to Maxygen's proprietary MAXY-G34 protein therapeutic for use in treating acute radiation syndrome.

17 Jul 2010

Personal injury lawsuit filed against Zimmer over defective hip implant

Kent L. Klaudt, a partner in the national plaintiffs' law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that James Cabral today filed a personal injury lawsuit against Zimmer Inc., the nation's largest producer of orthopedic devices. Cabral has suffered constant and devastating pain for over 18 months and will have to undergo a second hip replacement surgery due to an allegedly defective hip implant manufactured and sold by Zimmer under the brand name Durom Cup.

17 Jul 2010

Bone News and Research

NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers

Mesoblast gains Australian TGA licence to manufacture Mesenchymal Precursor Cell products

BioMimetic Therapeutics closes underwritten public offering

Genentech disappointed with FDA ODAC's recommendation against Avastin

CHLA receives $410,000 grant for 'first in childhood leukemia' multi-site study

KAI Pharmaceuticals completes enrollment in Phase 1 study of KAI-4169 for SHPT

European marine and algae oil omega-3 ingredient market to grow at 10% CAGR to reach $525.6M in 2013

Athletes who undergo tissue transplant surgery for knee damage can return to sports: Study

Researchers reveal findings on restricted lineage of iPS cells

CytRx updates on progress in clinical development of bafetinib in three oncology indications

Vitamin D supplements could help preteen girls set stage for a lifetime of strong bones: Study

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

ZIOPHARM Oncology commences palifosfamide Phase III clinical trial for metastatic soft tissue sarcoma

Arthroscopic hip surgery may help athletes resume their sport back: Study

Corgenix, ELITech establish broad strategic alliance

ThermoGenesis anticipates $7.3 million revenue for fourth-quarter 2010

Over 50% of neurosurgical procedures performed on Afghan children were for battlefield-related injuries

New mechanism that drives development of B-lymphocytes in bone marrow discovered

Maxygen's option and licensing arrangement with Cangene expires

Personal injury lawsuit filed against Zimmer over defective hip implant

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News